For diagnosis and therapy, prostate specific membrane antigen (PSMA) is used as a target as it is a type II membrane protein which is expressed in prostate tissue and in prostate carcinomas (Fendler et al. 2023). The gene discussed is FOLH1; the disease is prostate carcinoma.